Investors Research Corp Has $510,000 Holdings in Patterson Companies, Inc. (NASDAQ:PDCO)

Investors Research Corp boosted its position in Patterson Companies, Inc. (NASDAQ:PDCO) by 18.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,525 shares of the company’s stock after buying an additional 2,525 shares during the quarter. Investors Research Corp’s holdings in Patterson Companies were worth $510,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Moran Wealth Management LLC grew its stake in Patterson Companies by 4.7% in the 4th quarter. Moran Wealth Management LLC now owns 114,555 shares of the company’s stock valued at $3,535,000 after buying an additional 5,167 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Patterson Companies by 20.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,927 shares of the company’s stock valued at $738,000 after buying an additional 4,085 shares during the last quarter. Alpine Associates Management Inc. acquired a new stake in Patterson Companies in the 4th quarter worth $10,581,000. Amundi grew its position in Patterson Companies by 103.6% in the 4th quarter. Amundi now owns 47,230 shares of the company’s stock worth $1,457,000 after purchasing an additional 24,038 shares during the last quarter. Finally, Burren Capital Advisors Ltd acquired a new stake in Patterson Companies in the 4th quarter worth $1,659,000. 85.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PDCO has been the topic of several research analyst reports. Morgan Stanley raised their price target on shares of Patterson Companies from $27.00 to $31.35 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Leerink Partners restated a “market perform” rating and issued a $31.35 price target (up from $29.00) on shares of Patterson Companies in a research report on Wednesday, December 11th. Piper Sandler decreased their price target on shares of Patterson Companies from $26.00 to $24.00 and set a “neutral” rating on the stock in a research report on Friday, December 6th. Mizuho initiated coverage on shares of Patterson Companies in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $23.00 price target on the stock. Finally, Stifel Nicolaus decreased their price target on shares of Patterson Companies from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Thursday, December 5th. Eleven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $26.57.

Patterson Companies Price Performance

Shares of Patterson Companies stock opened at $31.12 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.76 and a current ratio of 1.37. The firm’s 50-day simple moving average is $30.98 and its 200-day simple moving average is $25.73. Patterson Companies, Inc. has a twelve month low of $19.45 and a twelve month high of $31.79. The firm has a market cap of $2.75 billion, a P/E ratio of 18.20, a price-to-earnings-growth ratio of 2.71 and a beta of 0.99.

About Patterson Companies

Patterson Companies, Inc engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems.